Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors
19 Agosto 2024 - 1:00PM
Business Wire
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology
company discovering and developing allogeneic gamma delta T cell
therapies for autoimmune diseases and cancer, today announced the
appointment of Lloyd Klickstein, M.D., Ph.D. to its Board of
Directors.
“We are pleased to welcome Dr. Klickstein to our Board of
Directors,” said Chen Schor, President and Chief Executive Officer
of Adicet Bio. “Dr. Klickstein’s expertise in rheumatology and
immunology, proven track record in drug development and his
scientific knowledge of our gamma delta T cell platform as a former
executive at Adicet will be very valuable as we progress our
autoimmune programs across multiple indications. I look forward to
working with Lloyd and to his contributions to our board and
pipeline of differentiated gamma delta CAR T therapies.”
“Leveraging its proprietary gamma delta T cell platform, Adicet
has the potential to develop groundbreaking therapies for
autoimmune and oncology indications. I am pleased to join the Board
of Directors at Adicet,” said Dr. Klickstein. “I look forward to
collaborating with my esteemed colleagues on the board and the
management team to drive Adicet's mission of delivering
best-in-class gamma delta cell therapies to patients in need.”
Dr. Klickstein has over two decades of leadership experience in
the biopharmaceutical industry and biomedical research. He
currently serves as President and Chief Executive Officer of
Koslapp Therapeutics, Inc. and is the Board Chair of the Lupus
Foundation of New England. Dr. Klickstein co-founded Versanis Bio,
Inc., where he held multiple executive roles, prior to the
Company’s acquisition by Eli Lilly and Co. Before that, he held
positions of Chief Innovation Officer at Adicet, Chief Scientific
Officer at resTORbio, Inc. (Adicet’s predecessor company) and
served as an independent board member at Blade Therapeutics, Inc.
Prior to that, Dr. Klickstein was the Global Head of Translational
Medicine for the New Indication Discovery Unit and the Exploratory
Disease Area at Novartis Institutes for Biomedical Research,
overseeing the development of innovative programs across various
therapeutic areas. Previously, he was an academic
physician-scientist at Brigham and Women’s Hospital (BWH). Dr.
Klickstein holds a B.S. from Tufts University and an M.D. and Ph.D.
from Harvard University. He completed post-graduate clinical
training in Internal Medicine, Rheumatology & Immunology at BWH
and a post-doctoral research fellowship at the Center for Blood
Research in Boston.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company
discovering and developing allogeneic gamma delta T cell therapies
for autoimmune diseases and cancer. Adicet is advancing a pipeline
of “off-the-shelf” gamma delta T cells, engineered with chimeric
antigen receptors (CARs), to facilitate durable activity in
patients. For more information, please visit the Company’s website
at https://www.adicetbio.com.
Forward-Looking Statements
This press release contains "forward-looking statements" of
Adicet within the meaning of the Private Securities Litigation
Reform Act of 1995 relating to the business and operations of
Adicet. The words “anticipate,” “believe,” “continue,” “could,”
“estimate,” “expect,” “intend,” “may,” “plan,” “potential,”
“predict,” “project,” “should,” “target,” “would” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. These forward-looking statements include, but
are not limited to, express or implied statements regarding:
Adicet’s expected growth as a company; Adicet’s plans and
expectations for advancing its autoimmune programs across multiple
indications; Adicet’s potential to develop best-in-class therapies
for autoimmune and oncology indications; and the anticipated
contribution of the members of Adicet’s Board of Directors to the
Company’s business.
Any forward-looking statements in this press release are based
on management’s current expectations and beliefs of future events,
and are subject to a number of risks and uncertainties that could
cause actual results to differ materially and adversely from those
set forth in or implied by such forward-looking statements,
including without limitation, the effect of global economic
conditions and public health emergencies on Adicet’s business and
financial results, including with respect to disruptions to our
preclinical and clinical studies, business operations, employee
hiring and retention, and ability to raise additional capital;
Adicet’s ability to execute on its strategy including obtaining the
requisite regulatory approvals on the expected timeline, if at all;
that positive results, including interim results, from a
preclinical or clinical study may not necessarily be predictive of
the results of future or ongoing studies; clinical studies may fail
to demonstrate adequate safety and efficacy of Adicet’s product
candidates, which would prevent, delay, or limit the scope of
regulatory approval and commercialization; and regulatory approval
processes of the U.S. Food and Drug Administration and comparable
foreign regulatory authorities are lengthy, time-consuming, and
inherently unpredictable; and Adicet’s ability to meet production
and product release expectations. For a discussion of these and
other risks and uncertainties, and other important factors, any of
which could cause Adicet’s actual results to differ from those
contained in the forward-looking statements, see the section
entitled “Risk Factors” in Adicet’s most recent quarterly report on
Form 10-Q and subsequent filings with the U.S. Securities and
Exchange Commission (SEC), as well as discussions of potential
risks, uncertainties, and other important factors in Adicet’s other
filings with the SEC. All information in this press release is as
of the date of the release, and Adicet undertakes no duty to update
this information unless required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240819541077/en/
Investors: Anne Bowdidge abowdidge@adicetbio.com
Janhavi Mohite Precision AQ 212-362-1200
Janhavi.mohite@precisionaq.com
Media: Kerry Beth Daly kbdaly@adicetbio.com
Grafico Azioni Adicet Bio (NASDAQ:ACET)
Storico
Da Gen 2025 a Feb 2025
Grafico Azioni Adicet Bio (NASDAQ:ACET)
Storico
Da Feb 2024 a Feb 2025
